A federal judge breathed new life into a long-running effort by the pharmaceutical industry to thwart a controversial California law that requires drug makers to not only provide advance notice of price hikes, but also give the reasons for any increases.

In a ruling on Wednesday, U.S. District Court Judge Morrison England Jr. allowed the PhRMA trade group to proceed with an amended lawsuit that argues the law is unconstitutional because it violates interstate commerce and free speech principles, unfairly holds drug makers largely accountable for prices, and purportedly has fuzzy language about the timeframe for providing notice of a price hike.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy